A Conceptual model on the pharmacogenomics implementation complications: An applied qualitative research based on national drug policy components

References

• 1.
  Ginsburg GS, McCarthy JJ. Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol 2001; 19: 491-496.
• 2.
  Johnson JA, Weitzel KW. Advancing pharmacogenomics as a component of precision medicine: how, where, and who? Clin Pharmacol Ther 2016; 99: 154-156.
• 3.
  Charlab R, Zhang L. Pharmacogenomics: historical perspective and current status. Methods Mol Biol 2013; 1015: 3-22.
• 4.
  Kasztura M, Richard A, Bempong NE, Loncar D, Flahault A. Cost-effectiveness of precision medicine: a scoping review. Int J Public Health 2019; 64: 1261-1271.
• 5.
  Plthner M, Ribbentrop D, Hartman J-P, Frank M. Cost-effectiveness of pharmacogenomic and pharmacogenetic test-guided personalized therapies: a systematic review of the approved active substances for personalized Mmedicine in Germany. Adv Ther 2016; 33: 1461-1480.
• 6.
  Tekola-Ayele F, Rotimi CN. Translational genomics in low- and middle-income countries: opportunities and challenges. Public Health Genom 2015; 18: 242-247.
• 7.
  Ghaddar F, Saba K, K Zgheib N. Teaching pharmacogenetics in low and middle income countries (LMICS): an empirical study of the lessons learned. Curr Pharmacogenomics Per Med 2012; 10: 217-225.
• 8.
  Pang T. Pharmacogenomics and personalized medicine for the developing world - Too soon or just-in-time? A personal view from the World Health Organization. Curr Pharmacogenomics Per Med 2009; 7: 149-157.
• 9.
  Patrinos GP, Pasparakis E, Koiliari E, Pereira AC, Hnemeier T, Pereira LV, et al. Roadmap for establishing large-scale genomic medicine initiatives in low- and middle-income countries. Am J Hum Genet 2020; 107: 589-595.
• 10.
  Mitropoulos K, Al Jaibeji H, Forero DA, Laissue P, Wonkam A, Lopez-Correa C, et al. Success stories in genomic medicine from resource-limited countries. Hum Genom 2015; 9: 11.
• 11.
  Chong HY, Allotey PA, Chaiyakunapruk N. Current landscape of personalized medicine adoption and implementation in Southeast Asia. BMC Genom 2018; 11.
• 12.
  Warnich L, I Drogemoller B, S Pepper M, Dandara C, EB Wright G. Pharmacogenomic research in South Africa: lessons learned and future opportunities in the rainbow nation. Curr Pharmacogenomics Per Med 2011; 9: 191-207.
• 13.
  Chong HY, Allotey PA, Chaiyakunapruk N. Current landscape of personalized medicine adoption and implementation in Southeast Asia. BMC Medical Genom 2018; 11.
• 14.
  Rafi I, Crinson I, Dawes M, Rafi D, Pirmohamed M, Walter F. The implementation of pharmacogenomics into UK general practice: a qualitative study exploring barriers, challenges and opportunities. J Community Genet 2020; 11: 269-277.
• 15.
  Bashir NS, Ungar WJ. The 3-I framework: a framework for developing public policies regarding pharmacogenomics (PGx) testing in Canada. Genome 2015; 58: 527-540.
• 16.
  Henderson LK, Craig JC, Willis NS, Tovey D, Webster AC. How to write a Cochrane systematic review. Nephrology 2010; 15: 617-624.
• 17.
  Eden C, Ackermann FJ. Cognitive mapping expert views for policy analysis in the public sector. Eur J Oper Res 2004; 152: 615-630.
• 18.
  Bergvall-Kreborn B, Mirijamdotter A, Basden A. Basic principles of SSM modeling: an examination of CATWOE from a soft perspective. Syst Pract Action Res 2004; 17: 55-73.
• 19.
  Wilson B. Soft systems methodology: Conceptual model building and its contribution. 2001.
• 20.
  Tuckson RV, Au SM, Berry CE, McGrath BB, Chen C, Evans JP, et al. Realizing the promise of pharmacogenomics: opportunities and challenges. Biotechnol Law Rep 2007; 26: 261-291.
• 21.
  Teutsch S, Tukson R. Realizing the potential of pharmacogenomics: opportunities and challenges. Report of secretary's advisory committee on genetics, health and society 2008; Available from: https://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/sacghs_pharmacogenomics_report1.pdf.
• 22.
  Lin JJ, Riely GJ, Shaw AT. Targeting ALK: Precision Medicine Takes on Drug Resistance. Cancer Discov 2017; 7: 137-155.
• 23.
  European U. European Commission Working Document2013 [cited 2019 July 28]. Available from: http://ec.europa.eu/health/files/latest_news/2013-10_personalised_medicine_en.pdf.
• 24.
  Knowles L, Luth W, Bubela T. Paving the road to personalized medicine: recommendations on regulatory, intellectual property and reimbursement challenges. J Law Biosci 2017; 4: 453-506.
• 25.
  Weda M. Personalized Medicine Products: Evaluation of Regulatory Framework. 2014.##.